Therefore, given the importance of B cells in RA pathogenesis, RA patients with a lymphoid synovial phenotype may be particularly well served by treatment with a BTK inhibitor in combination with an anti-TNF biologic. This evidence concerns the gene TNF and rheumatoid arthritis.